

Cherouveim P (1,2), Vagios S (1), Sassin A (1), Arkfeld C (1), Minis E (1), Dimitriadis I (1), Souter I (1)

(1) Massachusetts General Hospital Fertility Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; (2) Department of Obstetrics and Gynecology, Hurley Medical Center, Michigan State University, Flint, Michigan, USA

Introduction

- Autoimmune predisposition and its associated inflammation may influence endometrial development and implantation thereby predisposing pregnancies to placental-related complications such as preeclampsia, and fetal growth restriction.
- Preovulatory endometrial thickness (EMT) is often used as a sonographic proxy for endometrial growth and perfusion. Its development is often influenced by various treatment- and patient-related factors (the latter potentially including existing comorbidities).

Objective

- To investigate the association, if any, between autoimmune predisposition and preovulatory EMT in IUI/±OI cycles.

Methods

- Design:** Retrospective cohort.
- Setting:** Academic fertility center.
- Patients:** 4,482 patients undergoing 12,087 IUI/±OI cycles.
- Intervention:** Cycles were stratified into two groups, based on the presence or absence of an autoimmune disease [autoimmune (AI), vs. non-autoimmune (non-AI)]. EMT (mm) was compared between groups.
- Outcomes**
 - *Primary:* EMT (mm).
 - *Secondary:* Clinical pregnancy rate (CPR).
- Statistics:** Beta coefficients (β), odds ratios (OR), and their respective 95% confidence intervals (95%CI) were calculated using generalized estimating equations (GEE) regression analysis.

Table 1. Baseline characteristics between autoimmune groups.

	AI (N=473)	Non-AI (N=11614)	p-value
Age (years)	35.6 ± 3.6	35.1 ± 4.3	0.027
AMH (ng/ml)	3.5 ± 4.3	4.0 ± 4.4	<0.001
Day 3 FSH (U/L)	7.8 ± 3.5	7.6 ± 3.7	0.202
BMI (kg/m ²)	25.4 ± 5.4	25.0 ± 5.0	0.234


Numeric variables presented as Mean (SD), categorical variables presented as N (%).

Table 2. Unadjusted results for outcomes of interest between autoimmune groups.

	AI (N=473)	Non-AI (N=11614)	Total (N=12087)	p-value
EMT	8.3 (2.4)	8.5 (2.4)	8.5 (2.4)	0.430
CPR	64 (13.6%)	1253 (10.9%)	1317 (11.0%)	0.063

Numeric variables presented as Mean (SD), categorical variables presented as N (%).

Figure. Adjusted results for outcomes between groups (Reference: Non-AI)



Methods (cont'd)

- Statistics:** GEE models were used to account for more than one cycle per patient, and adjust for maternal age, body mass index, day-3 FSH, infertility diagnosis, number of days between last EMT measurement and HCG trigger, and OI, if any used (gonadotropins, clomiphene, letrozole), and natural cycles.

Methods (cont'd)

- The following three sub-analyses were performed:
 - cohort with cycles involving only Crohn's or Ulcerative colitis patients (Crohn's/UC)
 - cohort after exclusion of autoimmune thyroid conditions
 - cohort including gonadotropin-stimulated cycles only.

Results

- Baseline characteristics are presented in *Table 1*. Idiopathic infertility was the most common diagnosis in both AI (26.7%) and non-AI groups (31.7%).
- Prior to adjusting for confounders, EMT on the day of HCG trigger and CPR did not differ significantly between AI vs. non-AI, respectively (*Table 2*).
- After adjusting for confounders, no differences were noted in EMT between groups, either among all cycles or in either of the subanalyses (*Figure*).
- AdjOR(95%CI) suggested higher CPR with AI compared to non-AI among all cycles [1.35 (1.01, 1.82)] and among gonadotropin only cycles [1.63 (1.08, 2.46); non-AI as ref] (*Figure*).
- When analysis was limited to cycles from patients with either Crohn's/UC or excluding thyroid disorders, no differences were noted in adjOR(95%CI) CPR between groups (*Figure*).

Conclusions

- In this large retrospective cohort, autoimmune predisposition was not associated with impaired endometrial development or lower clinical pregnancy rates.
- Preserved endometrial thickness in patients with autoimmune conditions suggests that endometrial growth/perfusion is intact, supporting IUI/±OI as an appropriate option for patients with autoimmune conditions.